Taisho Acquires BMS Indonesia, OTC Assets; Price Tag Too High, Say Japanese Analysts
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Taisho Pharmaceutical, the largest OTC drug maker in Japan, has reached an agreement to acquire most outstanding shares of PT Bristol-Myers Squibb Indonesia and trademarks and other brand assets held in Asia by BMS, for roughly ¥28 billion ($310 million), Taisho announced Sept. 15
You may also be interested in...
Taisho Buys Malaysia's Leading Domestic Pharma To Build Distribution Hub For APAC
TOKYO - Taisho Pharmaceutical Co. Ltd., Japan's largest OTC manufacturer, carved out an entry in Southeast Asia with energy drink series Lipovitan, and now the company is looking to maximize its 2009 acquisition of Bristol-Myers Squibb Co.'s Asian OTC subsidiary through distribution channels from an acquisition of Malaysia's largest domestic pharmaceutical company
Taisho Buys Malaysia's Leading Domestic Pharma To Build Distribution Hub For APAC
TOKYO - Taisho Pharmaceutical Co. Ltd., Japan's largest OTC manufacturer, carved out an entry in Southeast Asia with energy drink series Lipovitan, and now the company is looking to maximize its 2009 acquisition of Bristol-Myers Squibb Co.'s Asian OTC subsidiary through distribution channels from an acquisition of Malaysia's largest domestic pharmaceutical company
Japan's Taisho Falters Under NHI Price Cuts; Eisai Squeezing Sales Out Of Aricept - Japanese Earnings Week
TOKYO - Taisho Pharmaceutical Co. said it operated in a difficult business environment in 2010, attributing weak sales to National Health Insurance price cuts and decreased demand for cold remedies